Skip to main content
US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
Screen a stock
TERMINAL
IV

IVBXFStockInnovent Biologics Inc

Healthcare

$10.93 last close 2026-11-19
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment IVBXF's does — no target price to set, unlike a price alert.

Sharia status
COMPLIANT
Per our secondary compliance provider · assessed 2026-07-10
Assessed 2026-07-10
Purification 3.25%

Methodology breakdown computing — it will appear here on its own.

🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
⚪ NEUTRAL — No Edge
Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.
Scores: 1 bullish / 1 bearish
39
of 100
Setup confidence — system conviction, not win probabilityD

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure0 of 3 timeframes bullish · 7.7% aligned
Momentum10-day rate of change -3.4%
Overall readNEUTRAL — No Edge

Innovent Biologics Inc (IVBXF) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-07-10). See the full ratio breakdown and business-activity screen below for the reasoning.

This sits among 435 compliant Healthcare stocks we track. See compliant Healthcare stocks →

Market & analysts
Institutional own.
59.2%
of shares
Momentum (10d)
-3.4%
rate of change
SMC grade
D · 39
7.7% aligned
D · 39
SMC grade — 7.7% timeframe alignment
-3.4%
Rate of change (10d)
59.2%
Institutional ownership

🕌 In-house Compliance Research

Computing the full ratio and business-activity breakdown for IVBXF — this runs off the critical path so the page paints first. It will appear here on its own.

Shariah-compliant alternatives

Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
VRTXVertex Pharmaceuticals, Inc. $121.1B —
REGNRegeneron Pharmaceuticals, Inc. $85.3B —
ARGXArgen X SE - ADR $64.3B —
ONCBeOne Medicines Ltd. American Depositary Shares $40.4B —
ALNYAlnylam Pharmaceuticals Inc $31.6B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

15.0113.5312.0510.589.102025-11-242026-05-272026-11-20

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance

Not enough completed daily bars to compute pivots.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
10.00 – 11.85
±8.42% from 10.93, made 2026-11-20 · resolves 2026-11-27
STRONG SELL
from 19 indicators
78.6% of our last 30385 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 53.9% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsSTRONG SELL
1 buy · 4 neutral · 2 sell
Moving averagesSTRONG SELL
1 buy · 0 neutral · 11 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)46.40NEUTRAL
Stochastic %K (14)64.87NEUTRAL
CCI (20)22.49NEUTRAL
Williams %R (14)-35.13NEUTRAL
MACD (12,26,9)0.05BUY
ROC (10)-1.53SELL
Momentum (10)-0.17SELL
EMA (10)10.97SELL
SMA (10)11.02SELL
EMA (20)11.09SELL
SMA (20)10.87BUY
EMA (30)11.25SELL
SMA (30)11.17SELL
EMA (50)11.48SELL
SMA (50)11.70SELL
EMA (100)11.58SELL
SMA (100)11.95SELL
EMA (200)11.28SELL
SMA (200)11.27SELL

About Innovent Biologics Inc

Healthcare · Biotechnology

Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverembatinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), DUPERT (fulzerasib), DOVBLERON (taletrectinib adipate), Jaypirca (pirtobrutinib), limertinib, SYCUME (teprotumumab N01 injection), mazdutide, PECONDLE (picankibart injection), and TABOSUN(Ipilimumab N01 injection). In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.

innoventbio.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Verdict

⚪ NEUTRAL — No Edge

Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.

Scores: 1 bullish / 1 bearish

Grade verdict

Weak — low conviction, small size or skip

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily RANGING 38
⏱ 15-Min RANGING 17
⏲ 5-Min BEARISH 51

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

Still fetching the volume profile — it ran past this page's budget, so the page painted without waiting. The fetch is still running; reload in a moment and it will be here.

-3.4%
Rate of change (10d)
-0.30
MACD (no fresh cross)

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-17 · Asset managers net 895049 (-19081)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.